Jake Leach

speaker

301 appearances 1 recordings 1 series first heard Feb 2026 last heard 19 Feb

Jake Leach’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Dexcom Aims to Expand CGM Benefits to All Diabetic Patients and Beyond · 19 Feb 2026 podcast

So it is quite a spectrum when it comes down to this non-reimbursed environment.

Yeah, the connection to snowstorms is a new one I hadn't heard yet, but you never know.

But the important thing around generating access for CGM, one of the most important things is building the evidence that shows the benefits people get from using the technology.

And so, as you mentioned, XCOM has been the leader in running all of the large randomized control trials that have opened up access for CGM for millions of people, starting with that diamond study you mentioned, which was for...

Patients with diabetes, either type 1 or type 2, that were taking multiple daily injections of insulin.

And so multiple, we call that intensive insulin therapy.

That study showed significant benefit for users that used the CGM.

And it was really a combination of CGM versus whatever the standard of care was at the time, which was really finger sticks.

And so that was how that study showed tremendous outcomes for those that used the CGM.

The mobile study you mentioned next was our study in basal insulin users.

And so that's the long-acting one injection per day.

Really, it's a type 2 therapy.

And so that study, again, showed significant improvements using CGM over, again, finger sticks.

What's really interesting about the next study that we're running is it's a randomized controlled trial in people with diabetes that don't use insulin.

So that's the majority of people with type 2 diabetes don't use insulin.

They use all sorts of other – their physicians prescribe them other medications to lower their glucose.

But the interesting thing is that group is very infrequently measuring their glucose.

They don't actually see it very often, and they certainly aren't seeing it continuously in the normal standards of care.

And so now with this study we're running, it's really comparing CGM use, continuous CGM use, with a standard of care, which is not measuring your glucose.

And so that has – we're really excited about that study.

Showing 161–180 of 301 · page 9 of 16